News

In Germany, HIV pre-exposure prophylaxis users are recommended to receive regular HIV, STI, and renal function testing. How frequently are PrEP users getting tested?

This year’s theme connects climate change and health.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) met today to discuss how to proceed with informing future COVID-19 vaccine strain composition and booster decisions.

After the US Food and Drug Administration (FDA) fully authorized the Pfizer-BioNTech mRNA vaccine, series-completing second doses increased substantially. However, first vaccine doses were actually administered at lower rates after the approval.

New data coming from Israel shows the Pfizer-BioNTech COVID-19 vaccine did offer some protection initially, but waning immunity occurs rapidly.

Bedaquiline-resistant tuberculosis is characterized in South Africa, where it has not been reserved as last resource for drug-resistant TB.

Being displaced by war is causing a disruption in treatment and long-term health care for Ukrainians. And it is likely, the situation will become more dire as the country’s public infrastructure worsens.

A new study found people who staunchly oppose COVID-19 vaccines were more likely to have experienced adverse childhoods, making them distrustful from a young age.

The voluntary recall issued by the company last December was investigated by federal, state and local partners.

Using CRISPR technology, investigators were able to “knock out” primary human CD4+ T cells, identifying new genes essential to HIV viral replication.

A meta-analysis showed that computerized cognitive training programs produced significant improvements in 6 cognitive and daily function domains among adults living with HIV.

A pair of new studies in the Journal of the American Medical Association add to growing evidence that COVID-19 vaccines are safe during pregnancy, showing no increased risk for adverse outcomes among women who were vaccinated during pregnancy and their babies.

The study authors wrote that selection bias at transmission can shape HIV disease severity and tolerance in different groups.

Children under 5 became infected with the Omicron variant 6-8 times more frequently than young children who contracted Delta. However, Delta COVID-19 infections were more severe than Omicron.

Here is a rundown of the most popular stories we covered this past week.

Despite lower comorbidity risk scores than Black or White COVID-19 patients, Mississippi’s Indigenous populations had significantly higher in-hospital mortality rates.

A recent study showed that 25% of mattresses within 4 hospitals required complete replacement, underlying a serious health risk that could lead to unnecessary infections.

The Food and Drug Administration (FDA) said the company is concerned about a limited number of jars that may contain a small fragment of stainless steel from a piece of manufacturing equipment.

The federal agency's new guidelines for adults between 19-59 years replaces risk-based recommendations.

2 doses of the Pfizer-BioNTech vaccine reduced Omicron hospitalizations by 68% in children 5-11 and by 40% in adolescents 12-18 years old.

Surveillance of N meningitidis finds that resistance is rare, with intermediate susceptibility to penicillin consistent year-to-year.

Today, the FDA approved the abacavir, dolutegravir, and lamivudine single tablet formulation Triumeq, a once-daily HIV treatment for children.

The Center for Global Development is launching a new working group, which aims to address antimicrobial resistance by exploring how to improve incentives for pharmaceutical companies to develop new antimicrobials for low-income and middle-income countries (LMICs).

The Pfizer-BioNTech and Moderna mRNA vaccines were found to produce different antibody and killer T-cell responses, suggesting a “mix and match” booster approach may provide the best protection against COVID-19.

“Together these 2 diseases create a perfect storm”: Black people with cancer were more likely to have severe or fatal COVID-19 disease.

New policy appears inconsistent and, on the surface, unfair, expert says.

Today, the FDA approved the long-acting HIV treatment Cabenuva (cabotegravir and rilpivirine dually administered) for virologically suppressed adolescents 12 years and older.

The new action by the federal agency now means the additional booster shot can be administered to people 50 years and older.